ClinicalTrials.gg
Enrolling by invitationNCT04565704Updated Nov 10, 2026

Optical Imaging of Gastrointestinal Biopsy Samples and Their Correlation With Histology

An interventional study of Biopsy imaged by Optical imaging device. in Gastrointestinal Disease and Gastrointestinal Dysfunction, sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled Mar 2016, registered Aug 2020).
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies in Gastrointestinal Diseases with a site in United States — 32 open to participants now, 42 under way, 5 of them phase 3. Gastrointestinal Diseases · United States.

Planned enrollment
32nd of 141
200 · median 90
Started
2016
with 11 others
No phase
63 of 200
13 open now
Primary completion
2028-12
later than 32 of 41 live
Registered
138th of 200
by date
Lead sponsor
6 of 200
Massachusetts General Hospital

Among the 200 studies in Gastrointestinal Diseases with a site in United States, this one is the 32nd largest by planned enrollment of the 141 interventional ones that give a count, is one of 12 that started in 2016, is one of 63 with no phase, reaches primary completion later than 32 of the 41 other live ones, and was the 138th registered.

Gastrointestinal Diseases

549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.

Browse Gastrointestinal Diseases studies →

Open to participants now

32 of the 200 studies in Gastrointestinal Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Gastrointestinal Diseases with a site in United States, or all of them as a file.
02

Study summary

To develop novel optical imaging technologies for use as a non-destructive and minimally invasive tool for detection and diagnosis of various diseases that affect the gastrointestinal system.

Read the detailed description

The investigators have previously developed optical imaging systems that have been able to provide highly detailed images of tissue structures in multiple application areas including Cardiology, Gastroenterology, and Pulmonology. They are looking to continue the advancement of these various technologies under development.

The population will include participants who are undergoing elective esophagogastroduodenoscopy with biopsy, colonoscopy with biopsy, and/or endo-mucosal resection.The endoscopist will take no more than 3 biopsies in addition to the standard of care biopsies.

The study will be optical imaging of the ex vivo GI specimens that are being collected. Specimens will be collected for research purposes only. Offline analysis of the samples will be performed, and optical imaging findings will be correlated with the pathology findings. This will require review of the medical record to link the findings of the imaging with the pertinent medical information. Samples will be de-identified and participants will be assigned a unique number. The tissues will be placed in marked containers labeled "for research purposes only". The samples collected will be brought to the Tearney Research Laboratory for imaging and processing. The Optical imaging of the tissue samples will not affect the standard of care procedure.

03

Conditions studied

  • Gastrointestinal Disease
  • Gastrointestinal Dysfunction

Keywords

  • OCT
  • Optical Coherence Tomography
  • Biopsy
  • GI disease
  • Endoscopy screening
  • Endoscopic Screening
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for an elective esophagoduodenoscopy and/or colonoscopy

Exclusion criteria

Exclusion Criteria:

  • According to standard of care at MGH endoscopy department.
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Development of novel optical imaging technologies

    Consented participants will allow their endoscopist to collect 3 additional biopsies from the participants. These biopsies will be used to develop our imaging techniques at our lab. We will use the standard of care histology images from the endoscopy procedure as a control comparison.

    Device: Biopsy imaged by Optical imaging device.

Interventions

  • DeviceBiopsy imaged by Optical imaging device.
06

What researchers measure

Primary outcomes

  1. Device Feasibility based on image quality and presence of microscopic features

    The feasibility will be determined by at least one of the following parameters: 1) assessing image adequacy (resolution, contrast, etc.) qualitatively, 2) confirming that microscopic features observed in the images are also seen by correlative histopathology, 3) ability to develop preliminary criteria or algorithms based on image-histopathology matches.

    Time frame: Imaging data is collected during the procedure, and analyzed within 1 year of collection.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2016 (actual). Primary completion is estimated for Dec 2028, 153 months after the start.

Of 127 non-industry interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 153 months is above that.

Counting every sponsor, half of 149 studies reached it within 24 months; a quarter within 10 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2027 → Dec 2028 and completion Dec 2028 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Sep 25, 2020
StartActual
Mar 25, 2016
Primary completionEst.
Dec 31, 2028was Dec 2027
CompletionEst.
Dec 31, 2029was Dec 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2027→Dec 31, 2028
Nov 10, 2026
Study completion
Dec 31, 2028→Dec 31, 2029
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Dec 31, 2027→Dec 31, 2028
    Study completion Dec 31, 2028→Dec 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04565704
Responsible party
Guillermo Tearney (Principal Investigator - MD, PhD, FACC, FCAP, FNAI, Massachusetts General Hospital) — Principal investigator
First posted
Sep 25, 2020
Start date
Mar 25, 2016
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Guillermo Tearney, M.D, PhD.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion